Abstract Number: 123 • 2020 Pediatric Rheumatology Symposium
Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Those with Sacroiliitis
Background/Purpose: To describe characteristics of children with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA)…Abstract Number: 2709 • 2019 ACR/ARP Annual Meeting
Secukinumab Is a Promising Treatment for Patients with Juvenile Enthesitis Related Arthritis Nonresponsive to Anti-TNF Treatment According the Juvenile Spondyloarthritis Disease Activity Index
Background/Purpose: Secukinumab (SEC) is licensed to treat adults with spondyloarthritis and psoriatic arthritis. It is not licensed for juvenile patients yet. As biologic agents up…Abstract Number: 2713 • 2019 ACR/ARP Annual Meeting
Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Those with Sacroiliitis
Background/Purpose: Herein we describe characteristics of children with juvenile spondyloarthritis (JSpA, i.e. enthesitis-related arthritis [ERA] or juvenile psoriatic arthritis [JPsA]) enrolled in the Childhood Arthritis…Abstract Number: 1436 • 2018 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Partners of DMARD Exposed Men with Juvenile Idiopathic Arthritis – an Observational Study
Background/Purpose: Males account for about one third of all cases of juvenile idiopathic arthritis (JIA). During the course of the disease and often into adulthood,…Abstract Number: 2386 • 2018 ACR/ARHP Annual Meeting
Secukinumab Is a Promising Treatment for Patients with Juvenile Enthesitis Related Arthritis Nonresponsive to Anti-TNF Treatment
Background/Purpose: Secukinumab (SEC) is licensed to treat adults with spondyloarthritis. It is not licensed for pediatric patients with Juvenile Idiopathic Enthesitis related Arthritis (enthJIA) yet.…Abstract Number: 2288 • 2017 ACR/ARHP Annual Meeting
Successful Treatment of Methotrexate Intolerance in Juvenile Idiopathic Arthritis Using Eye Movement Desensitization and Reprocessing (EMDR)
Background/Purpose: Methotrexate (MTX) is commonly used in the treatment of children with juvenile idiopathic arthritis (JIA). It frequently has to be discontinued due to intolerance…Abstract Number: 2296 • 2017 ACR/ARHP Annual Meeting
Infliximab Use in JIA and Uveitis: Does Methotrexate Help or Hinder?
Background/Purpose: Infliximab (IFX) effectiveness is impacted in part by immunogenicity and the development of drug neutralizing anti-drug antibodies, thus methotrexate is commonly co-administered to minimize…Abstract Number: 2329 • 2017 ACR/ARHP Annual Meeting
Monocytes from Patients with Enthesitis Related Arthritis Produce High Levels of Pro-Inflammatory Cytokines: Role of Endogenous Ligands
Background/Purpose: HLA B27 and gut bacteria are postulated to play a role in pathogenesis of Enthesitis Related Arthritis. Gut microbes can activate monocytes/macrophages by TLR…Abstract Number: 2333 • 2017 ACR/ARHP Annual Meeting
Adjudication of Infections from the Pharmacovigilance in Juvenile Idiopathic Arthritis Patients (PHARMACHILD) Treated with Biologic Agents and/or Methotrexate with a Focus on Opportunistic Infections
Background/Purpose: Pharmachild is a pharmacovigilance registry on children with JIA treated mainly with biologics ± methotrexate (MTX). Little evidence exists in literature about the role…Abstract Number: 950 • 2016 ACR/ARHP Annual Meeting
Flares after Withdrawal of Biotherapies in JIA: Clinical and Laboratory Correlates of Remission Duration
Background/Purpose: Information regarding the history of patients with JIA after systemic treatment withdrawal would be helpful in driving the choice of duration therapy. While some…Abstract Number: 1455 • 2015 ACR/ARHP Annual Meeting
Juvenile Spondyloarthropathies: a Single Center Experience
Background/Purpose: : Juvenile spondyloarthropathies (JSpA) are a group of chronic childhood rheumatic diseases which emerge especially before 16 and after 6 years-old. While enthesitis and…Abstract Number: 2451 • 2015 ACR/ARHP Annual Meeting
Scoring Medication Requirements and Side-Effects in Juvenile Idiopathic Arthritis: Perspectives of Patients, Parents and Clinicians
Background/Purpose: Medication requirements (MedReq) and medication side effects (MedSE) were found to be top priorities by patients, parents and clinicians in describing the course of…Abstract Number: 2288 • 2014 ACR/ARHP Annual Meeting
The Research in Arthritis in Canadian Children Emphasizing Outcomes (ReACCh Out) Cohort: Independent Risk Factors and Medication Use in New Onset Uveitis in Juvenile Idiopathic Arthritis
Background/Purpose: The Research in Arthritis in Canadian Children emphasizing Outcomes (ReACCh Out) cohort is a multi-centre prospective inception cohort of newly diagnosed Juvenile Idiopathic Arthritis…Abstract Number: L14 • 2014 ACR/ARHP Annual Meeting
Determination of Efficacy of Intra-Articular Infliximab Therapy in JIA Patients By 3D/4D Musculo-Skeletal Ultrasound
Background/Purpose: Intra-articular (IA) infliximab (IFX) is an attractive treatment option of chronic arthritis, but based on few heterogenic studies, outcome is still controversial. To investigate…Abstract Number: 2789 • 2013 ACR/ARHP Annual Meeting
Enhancing Uveitis Screening Compliance In Juvenile Idiopathic Arthritis Patients
Background/Purpose: Chronic uveitis is one of the more severe morbidities associated with juvenile idiopathic arthritis (JIA). Risk of developing uveitis, and the frequency of uveitis…